SCHEMBL28980916

SCHEMBL28980916

COC(=O)CNC(=O)C1CNCCN1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.38
TSHR P16473 1/20 0.38
TET2 Q6N021 1/20 0.38
EPHX2 P34913 1/20 0.37
RECQL P46063 1/20 0.37
PRCP P42785 2/20 0.36
CHRNB2 P17787 4/20 0.35
CHRNA4 P43681 4/20 0.35
CHRNA7 P36544 2/20 0.35
CHRNB4 P30926 2/20 0.35
CHRNA3 P32297 2/20 0.35
KDM4E B2RXH2 3/20 0.34
ALDH1A1 P00352 1/20 0.34
AKT2 P31751 1/20 0.32
HTT P42858 1/20 0.32
GAA P10253 1/20 0.31
HTR2C P28335 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19996549 0.81 PRCP (0.45) PRCPCHRNB2CHRNA4CHRNA7CHRNB4
SCHEMBL5234117 0.79 PRCP (0.55) EPHX2PRCPKDM4EHTR2C
SCHEMBL5234110 0.79 PRCP (0.55) EPHX2PRCPKDM4EHTR2C
SCHEMBL6626467 0.77 PRCP (0.53) PRCPCHRNB2CHRNA4CHRNA7CHRNB4
SCHEMBL30049017 0.76 L3MBTL1 (0.37) CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3
SCHEMBL6973885 0.76 CHRNB2 (0.35) PRCPCHRNB2CHRNA4CHRNA7CHRNB4
SCHEMBL7028322 0.75 PRCP (0.34) PRCPAKT2HTR2C
SCHEMBL7028320 0.75 PRCP (0.34) PRCPAKT2HTR2C
SCHEMBL14395328 0.75 PRCP (0.34) PRCPAKT2HTR2C
SCHEMBL20366276 0.75 HTR2C (0.48) HSD17B10TSHRTET2EPHX2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240101562-A1 NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESISTANT CANCER, COMPRISING SAME HOLOSMEDIC (KR) 2024-03-28 US disclosed
EP-4174068-A1 NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESISTANT CANCER, COMPRISING SAME Holosmedic (KR) 2023-05-03 EP disclosed
CN-115916206-A Novel compound and pharmaceutical composition for preventing or treating resistant cancer comprising same 治愈医药社株式会社 2023-04-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101562-A1 NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESISTANT CANCER, COMPRISING SAME SLC11A2, ABCC1, TSG101 HSD17B10 1797/4885TSHR 4766/4885TET2 3982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.